These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 11197147)

  • 1. Plasma beta-phenylethylamine in Parkinson's disease.
    Miura Y
    Kurume Med J; 2000; 47(4):267-72. PubMed ID: 11197147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet monoamine oxidase B and plasma beta-phenylethylamine in Parkinson's disease.
    Zhou G; Miura Y; Shoji H; Yamada S; Matsuishi T
    J Neurol Neurosurg Psychiatry; 2001 Feb; 70(2):229-31. PubMed ID: 11160474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased beta-phenylethylamine in CSF in Parkinson's disease.
    Zhou G; Shoji H; Yamada S; Matsuishi T
    J Neurol Neurosurg Psychiatry; 1997 Dec; 63(6):754-8. PubMed ID: 9416810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition.
    Clarke A; Brewer F; Johnson ES; Mallard N; Hartig F; Taylor S; Corn TH
    J Neural Transm (Vienna); 2003 Nov; 110(11):1241-55. PubMed ID: 14628189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma phenylethylamine and phenylalanine in chronic schizophrenic patients.
    Szymanski HV; Naylor EW; Karoum F
    Biol Psychiatry; 1987 Feb; 22(2):194-8. PubMed ID: 3814669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concentrations of beta-phenylethylamine in plasma and plateletes of schizophrenics.
    Myojin T; Taga C; Tsuji M
    Jpn J Psychiatry Neurol; 1989 Jun; 43(2):171-6. PubMed ID: 2796027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The measurement of beta-phenylethylamine in human plasma and rat brain.
    Huebert ND; Schuurmans Schwach V; Richter G; Zreika M; Hinze C; Haegele KD
    Anal Biochem; 1994 Aug; 221(1):42-7. PubMed ID: 7985801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-phenylethylamine and noradrenergic function in depression.
    Nakagawara M
    Prog Neuropsychopharmacol Biol Psychiatry; 1992 Jan; 16(1):45-53. PubMed ID: 1557506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A kinetic analysis of the effects of beta-phenylethylamine on the concentrations of dopamine and its metabolites in the rat striatum.
    Sato S; Tamura A; Kitagawa S; Koshiro A
    J Pharm Sci; 1997 Apr; 86(4):487-96. PubMed ID: 9109054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropharmacological and neurochemical properties of N-(2-cyanoethyl)-2-phenylethylamine, a prodrug of 2-phenylethylamine.
    Baker GB; Coutts RT; Rao TS
    Br J Pharmacol; 1987 Oct; 92(2):243-55. PubMed ID: 2890391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson's disease patients.
    Swanson CR; Berlyand Y; Xie SX; Alcalay RN; Chahine LM; Chen-Plotkin AS
    Mov Disord; 2015 Oct; 30(12):1648-56. PubMed ID: 26207725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma levels of inorganic sulfates in patients with Parkinson's disease.
    Jiménez-Jiménez FJ; Molina JA; Aguilar MV; Jorge-Santamaría A; Mateos-Vega CJ; González-Muñoz MJ; Cabrera-Valdivia F; Ayuso-Peralta L; Benito J; Vázquez A
    Acta Neurol Scand; 1995 Nov; 92(5):369-71. PubMed ID: 8610488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma levels of nitrates in patients with Parkinson's disease.
    Molina JA; Jiménez-Jiménez FJ; Navarro JA; Ruiz E; Arenas J; Cabrera-Valdivia F; Vázquez A; Fernández-Calle P; Ayuso-Peralta L; Rabasa M
    J Neurol Sci; 1994 Dec; 127(1):87-89. PubMed ID: 7699396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of plasma phenylethylamine by combined gas chromatography/electron capture negative ion mass spectrometry of the N-acetyl-N-pentafluorobenzoyl derivative.
    Durden DA; Davis BA; Boulton AA
    Biol Mass Spectrom; 1991 Jun; 20(6):375-81. PubMed ID: 1888782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mass fragmentographic demonstration of low amounts of beta-phenylethylamine in human urine.
    Andersen H; Braestrup C
    Scand J Clin Lab Invest; 1977 Feb; 37(1):33-7. PubMed ID: 616024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between the plasma levels of neurodegenerative proteins and motor subtypes of Parkinson's disease.
    Ding J; Zhang J; Wang X; Zhang L; Jiang S; Yuan Y; Li J; Zhu L; Zhang K
    J Neural Transm (Vienna); 2017 Mar; 124(3):353-360. PubMed ID: 27878377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Parkinson's disease-related pain with plasma interleukin-1, interleukin-6, interleukin-10, and tumour necrosis factor-α.
    Li D; Song X; Huang H; Huang H; Ye Z
    Neurosci Lett; 2018 Sep; 683():181-184. PubMed ID: 30063943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolomic biomarkers as strong correlates of Parkinson disease progression.
    LeWitt PA; Li J; Lu M; Guo L; Auinger P;
    Neurology; 2017 Feb; 88(9):862-869. PubMed ID: 28179471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma homocysteine level and its relationship to clinical profile in Parkinson's disease patients at the Lagos University Teaching Hospital.
    Ojo OO; Oladipo OO; Ojini FI; Sanya EO; Danesi MA; Okubadejo NU
    West Afr J Med; 2011; 30(5):319-24. PubMed ID: 22752818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electron-capture gas chromatographic analysis of beta-phenylethylamine in tissues and body fluids using pentafluorobenzenesulfonyl chloride for derivatization.
    Baker GB; Rao TS; Coutts RT
    J Chromatogr; 1986 Sep; 381(2):211-7. PubMed ID: 3760080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.